Obesity; Endocrine, Pre-Eclampsia
Conditions
Keywords
CTRP, Adipocytokines, pre-eclampsia
Brief summary
The complement C1q tumor necrosis factor-associated protein-9 (CTRP-9), which is responsible for regulating cardiovascular and metabolic functions, increases vascular relaxation by pathway dependent on AMPK / endothelial nitric oxide synthesis (eNOS). The aim of this study was to investigate CTRP-9 levels in pregnant women with preeclampsia.
Detailed description
The most important reason for the development of preeclampsia is the problem of trophoblastinvasion and consequent formation and development of placenta is not healthy Cytokines are regulatory molecules that have effects on cell functions.Cytokines are molecules that also regulate endothelial functions. Placenta formation and widespread endothelial damage are under the influence of cytokines. Therefore, there may be important links between impairment or imbalance in cytokine release and function and the formation of preeclampsia.Nitric oxide (NO) is a biologic enzyme that is synthesized by nitric oxide synthase (NOS) from the amino acid of L-arginine and exists in all mammals. e(NOS) is the three isoforms of NO. It is known that NO is a major vasodilator of pregnancy, inhibiting platelet and leukocyte aggregation.There was a decrease in NO levels in preeclamptic patients. The CqP / TNF Binding Protein (CTRP) family consists of 15 members, and is synthesized in many organs outside the body of fat.CTRP9 is predominantly excreted in fat tissue, and levels in circulation are reduced in patients with diabetes and obesity.Many studies have shown that CTRP9 exerts beneficial effects on metabolic and cardiovascular homeostasis. CTRP9 increases vascular relaxation in the AMPK / endothelial nitric oxide synthase (eNOS) dependent pathway. CTRP9 has also been reported to reduce inflammatory responses in endothelial cells via the AMPK-dependent pathway. Vasorelaxation due to CTRP9 is endothelium-dependent and NO-mediated. CTRP9, directly acting on smooth muscle, is indirectly or indirectly associated with NO production in the vascular endothelial layer by stimulating vasorelaxial molecular production by endothelial cells.
Interventions
DIAGNOSTIC_TESTBlood test
For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
Sponsors
Diyarbakir Women's and Children's Diseases Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)
Intervention model description
40 obese preeclamptic pregnant women 40 non-obese preeclamptic pregnant women 40 normal pregnant women
Eligibility
Sex/Gender
FEMALE
Age
15 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Pregnant women who are ages 15-40 * BMI ≥35 kg/m2 and BMI\<25 KG/m2 pregnants * The clinical diagnosis of preeclampsia will follow the current criteria outlined by ACOG 10 * \> 20 th weeks of pregnancy
Exclusion criteria
* A previously known chronic metabolic disease (diabetes, pregestational dyslipidemia, hypertension,) * collagen vascular diseases, * inflammatory bowel disease * chronic inflammatory conditions,
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CTRP 9 level in preeclamptic pregnancies | 3 months | Blood samples were taken from patients with preeclampsia. The diagnosis was made when the arterial blood pressure was above 140/90 mm / Hg within 6 hours and was accompanied by proteinuria (\> 300 milligrams in a sample) with high blood pressure and number of patients with proteinuria (ACOG criteria) |
Countries
Turkey (Türkiye)
Outcome results
None listed